N. Engl. J. Med.
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
ABSTRACT
BACKGROUND
Data are lacking on the efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) as compared with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer.
METHODS
We randomly assigned 342 patients with an Eastern Cooperative Oncology Group performance status score of 0 or 1 (on a scale of 0 to 5, with higher scores indicating a greater severity of illness) to receive FOLFIRINOX (oxaliplatin, 85 mg per square meter of body-surface area; irinotecan, 180 mg per square meter; leucovorin, 400 mg per square meter; and fluorouracil, 400 mg per square meter given as a bolus followed by 2400 mg per square meter given as a 46-hour continuous infusion, every 2 weeks) or gemcitabine at a dose of 1000 mg per square meter weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks. Six months of chemotherapy were recommended in both groups in patients who had a response. The primary end point was overall survival.
RESULTS
The median overall survival was 11.1 months in the FOLFIRINOX group as compared with 6.8 months in the gemcitabine group (hazard ratio for death, 0.57; 95% confidence interval [CI], 0.45 to 0.73; P<0.001). Median progression-free survival was 6.4 months in the FOLFIRINOX group and 3.3 months in the gemcitabine group (hazard ratio for disease progression, 0.47; 95% CI, 0.37 to 0.59; P<0.001). The objective response rate was 31.6% in the FOLFIRINOX group versus 9.4% in the gemcitabine group (P<0.001). More adverse events were noted in the FOLFIRINOX group; 5.4% of patients in this group had febrile neutropenia. At 6 months, 31% of the patients in the FOLFIRINOX group had a definitive degradation of the quality of life versus 66% in the gemcitabine group (hazard ratio, 0.47; 95% CI, 0.30 to 0.70; P<0.001).
CONCLUSIONS
As compared with gemcitabine, FOLFIRINOX was associated with a survival advantage and had increased toxicity. FOLFIRINOX is an option for the treatment of patients with metastatic pancreatic cancer and good performance status. (Funded by the French government and others; ClinicalTrials.gov number, NCT00112658.).
Related Questions
How would you approach this situation in the absence of BRCA mutation data?
New comment by Medical Oncologist at Los Angeles VA Medical Center ( September 7, 2019)
I've seen similar approaches to Dr. Reiss Binder's by dropping oxaliplatin/most cumulative toxicity, modeled somewhat off this French phase 2 study presented at ASCO 2018 that...
Do you treat with radiation therapy and what dose do you use? What dose do you accept to the duodenum?
Would you consider switching to a different regimen?
New answer by Medical Oncologist at UPMC Cancer Center (July 15, 2022)
Great question in a challenging subset of patients with a disease process with very poor outcomes. If no radiographic response and CA19-9 response, we would switch to Gem/Abra...
Given the recent update from the NAPOLI-3 trial presented at GI ASCO 2023, the two regimens appear to have similar OS.
New answer by Medical Oncologist at University of Utah Huntsman Cancer Institute (April 28, 2024)
Fully agree with answers/comments above that with current evidence I cant see any scenario where I would use NALIRIFOX instead of FOLFIRINOX.There is no difference in neurotox...